Key Market Insights
- Over 100 bacteriophage therapeutics have either been marketed / are being developed by various well-established and small firms; majority of these therapeutics are being evaluated for the treatment of infectious diseases
- Around 50% of the pipeline candidates are currently under clinical phase of development; of these, close to 50% are designed for oral and topical administration
- Multiple clinical studies, evaluating various types of bacteriophage therapeutics among more than 3,000 patients across different centers / hospitals, have been registered worldwide
- Over the years, the intellectual capital related to bacteriophage therapeutics has grown at a significant pace, with several patents being filed by both industry and non-industry players
- A notable increase in published scientific literature related to bacterio-phage therapeutics has been observed over the years, demonstrating the growing interest in this domain
- Various organizations have extended financial support to aid the ongoing research for bacteriophage therapies; currently, the focus, in terms of funds disbursed, is on clinical investigation of bacteriophage therapeutics
- Several investors, having realized the benefits and future opportunity, have invested over USD 1 billion since 2017
- The rising interest of stakeholders is also reflected by the number of partnerships signed in the recent past, involving players located in different geographical regions
- Our proprietary start-up health indexing analysis confirms the presence of several new entrants that claim to possess the required capabilities for developing bacteriophage therapeutics
- The bacteriophage market is anticipated to grow at a CAGR of ~10% till 2035; the forecasted opportunity is likely to be distributed across different therapeutic areas, routes of administration, and geographical regions
Table of Content
- PREFACE
1.1. Scope of the Report
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
- EXECUTIVE SUMMARY
- INTRODUCTION
3.1. Chapter Overview
3.2. Historical Evolution of Bacteriophages
3.3. Biology of Bacteriophages
3.4. Introduction to Bacteriophage Therapy
3.5. Applications of Bacteriophage Therapy
3.6. Advantages of Bacteriophage Therapy
3.7. Limitations of Bacteriophage Therapy
3.8. Conclusion
- BACTERIOPHAGE THERAPEUTICS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Bacteriophage Therapeutics: Drug Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Therapeutic Area
4.2.3. Analysis by Phase of Development and Therapeutic Area
4.2.4. Analysis by Targeted Bacterial Strain
4.2.5. Analysis by Target Disease Indication
4.2.6. Analysis by Type of Therapy
4.2.7. Analysis by Route of Administration
4.3. Information on Bacteriophage Related Technologies
- BACTERIOPHAGE THERAPEUTICS: DEVELOPER LANDSCAPE
5.1. Chapter Overview
5.2. Bacteriophage Therapeutics: List of Developers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Company Size and Location of Headquarters
5.2.5. Leading Developers: Analysis by Number of Bacteriophage Therapeutics
- COMPANY AND DRUG PROFILES
6.1. Chapter Overview
6.2. Eliava BioPreparations
6.3. Micreos
6.4. NPO Microgen
6.5. ContraFect
6.6. Adaptive Phage Therapeutics
6.7. Phagelux
6.8. Pherecydes Pharma
- CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Bacteriophage Therapeutics Market: Clinical Trial Analysis
- PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Bacteriophage Therapeutics: Patent Analysis
8.4. Bacteriophage Therapeutics: Patent Benchmarking
8.5. Bacteriophage Therapeutics: Patent Valuation
8.6. List of Leading Patents
- PUBLICATION BENCHMARKING ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Publication Benchmarking
- ACADEMIC GRANTS ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Bacteriophage Therapeutics: Academic Grant Analysis
- FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Bacteriophage Therapeutics Market: List of Funding and Investments
11.4. Concluding Remarks
- PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. Bacteriophage Therapeutics: List of Partnerships and Collaborations
- START-UP HEALTH INDEXING
13.1. Chapter Overview
13.2. Bacteriophage Therapeutics Developers: Start-ups
13.3. Benchmarking of Start-ups
- MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Scope and Assumptions
14.3. Forecast Methodology
14.4. Global Bacteriophage Therapeutics Market, 2022-2035
- CONCLUSION
- EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Rime Bioinformatics
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Antoine Culot, Chief Executive Officer
16.3. BiomX
16.4. Hospices Civils De Lyon
16.5. Independent Consultant
- APPENDIX I: TABULATED DATA
- APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
For additional details, please visit https://www.rootsanalysis.com/reports/bacteriophage-therapy-market.html
You may also be interested in the following titles:
Nanoparticle Formulation Market
mRNA Therapeutics and mRNA Vaccines Industry: Current Scenario and Future Trends
Cell Therapy Manufacturing Market
Roots Analysis Consulting - the preferred research partner for global firms
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
